Camicinal

Camicinal is a motilin agonist for the treatment of gastroparesis.[1][2][3]

Camicinal
Clinical data
Other namesGSK962040
Identifiers
PubChem CID
ChemSpider
KEGG
ECHA InfoCard100.158.139
Chemical and physical data
FormulaC25H33FN4O
Molar mass424.564 g·mol−1
3D model (JSmol)

References

  1. Barshop, Kenneth; Kuo, Braden (24 October 2014). "The investigational drug camicinal for the treatment of gastroparesis". Expert Opinion on Investigational Drugs. 24 (1): 133–140. doi:10.1517/13543784.2015.975792. PMID 25341626.
  2. Hobson, R.; Farmer, A. D.; Dewit, O. E.; O'Donnell, M.; Hacquoil, K.; Robertson, D.; Barton, M. E.; Dukes, G. E. (November 2015). "The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial". Neurogastroenterology & Motility. 27 (11): 1629–1637. doi:10.1111/nmo.12663. PMID 26348542.
  3. Chapman, MJ; Deane, AM; O'Connor, SL; Nguyen, NQ; Fraser, RJ; Richards, DB; Hacquoil, KE; Vasist Johnson, LS; Barton, ME; Dukes, GE (1 August 2016). "The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial". Critical Care (London, England). 20 (1): 232. doi:10.1186/s13054-016-1420-4. PMC 4967996. PMID 27476581.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.